ライフサイエンスコーパス: cancer-testis antigen

1 d in various human tumors, defining SSX as a cancer/testis antigen.

2 TRAG-3 has been reported to be a cancer/testis antigen.

3 demethylation of endogenous retroviruses and cancer testis antigens.

4 en (HLA)-presented immunopeptides, including cancer testis antigens.

5 and in some cases shared differentiation or cancer-testis antigens.

6 topes predominantly from differentiation and cancer-testis antigens.

7 esponses as opposed to hepatitis B virus and cancer-testis antigens.

8 mmon regulatory mechanisms for this group of cancer-testis antigens.

9 d putative new biomarkers, drug targets, and cancer/testis antigens.

10 t SPAN-Xb is a novel member of the family of cancer/testis antigens aberrantly expressed by, and capa

11 er 1, is characterized by high expression of cancer testis antigen and proliferation-associated genes

12 ssed in the medulloblastoma include PRAME, a cancer-testis antigen and potential targets for immunoth

13 action between melanoma antigen-11 (MAGE-11) cancer-testis antigen and the major HIF-alpha hydroxylat

14 -PCR analysis demonstrates that SPAN-Xb is a cancer/testis antigen and shows a restricted normal tiss

15 the identification of peptides derived from cancer/testis antigens and patient specific neoantigens.

16 ecific traits included expression of several cancer/testis antigens and the c-kit proto-oncogene thro

17 tissue differentiation antigens), NY-ESO-1 (cancer/testis antigen) and survivin (inhibitor of apopto

18 immune cell content and correlated with TMB, cancer testis antigens, and TP53 mutations.

19 of choice include mutant sequences, selected cancer testis antigens, and viral antigens.

20 ve mainly targeted differentiation antigens, cancer-testis antigens, and overexpressed antigens and h

21 immunogenic alterations, neoantigens, common cancer/testis antigens, and the immune microenvironment,

22 In contrast to the fact that many cancer/testis antigens are poorly immunogenic, the TAG-d

23 sine residue at position 124 of the NY-ESO-1 cancer/testis antigen as the acceptor site for the forma

24 st that CSAGE belongs to the growing list of cancer/testis antigens as well.

25 Cancer/testis antigen cancer-associated gene (CAGE) is k

26 o discover CD4+ TCRs of optimal affinity for cancer testis antigen (CTA) NY-ESO-1.

27 The cancer testis antigen (CTA) preferentially expressed ant

28 The cancer testis antigen (CTA) preferentially expressed ant

29 Its product is a cancer testis antigen (CTA), and it is often expressed i

30 Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1,

31 Here, we describe the de novo induction of a cancer/testis antigen (CTA) for immunotherapy of tumors

32 elanoma-associated antigen A4 (MAGE-A4) is a cancer/testis antigen (CTA) that interacts with the E3 u

33 Many MGCA are also expressed as cancer/testis antigens (CTA) in human cancers, but the t

34 es in the tumor lines, 6 were members of the cancer/testis antigen (CTAG) gene group including 5 MAGE

35 Cancer testis antigens (CTAgs) are expressed by the majo

36 Cancer testis antigens (CTAs) are a collection of protei

37 Cancer testis antigens (CTAs) are proteins whose express

38 tiated phenotype marked by overexpression of cancer testis antigens (CTAs) including anti-apoptotic m

39 Cancer testis antigens (CTAs) represented a poorly chara

40 MAGE proteins are cancer testis antigens (CTAs) that are characterized by

41 Cancer-testis antigens (CTAs) are normally expressed in

42 Neoantigens (neoAgs) and cancer-testis antigens (CTAs) are tumor-specific targets

43 Cancer-testis antigens (CTAs) represent promising target

44 ins aberrantly expressed in cancer, known as cancer-testis antigens (CTAs), are often pursued as canc

45 biased to the testis, collectively known as cancer-testis antigens (CTAs).

46 The cancer/testis antigens (CTAs) are an important group of

47 PRAME belongs to a group of cancer/testis antigens (CTAs) that are characterized by

48 -expressed in soma-derived human cancers as "cancer/testis antigens" (CTAs), and piRNA (PIWI-interact

49 al transition; (c) coordinated activation of cancer/testis antigens; (d) coordinated down-regulation

50 NY-ESO-1 is a "cancer-testis" antigen expressed in epithelial ovarian c

51 melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in mul

52 It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subset of patients

53 cancers exhibiting increased mutation load, cancer-testis antigen expression, and intratumoral heter

54 responses than women, likely due to gonadal cancer-testis-antigen expression.

55 Analysis of cancer/testis antigen expression and CD8 T-cell abundanc

56 ssion of MAGEA2, and related members of this cancer-testis antigen family, is upregulated in tamoxife

57 POTE is a new primate-specific member of the cancer-testis antigen family.

58 BORIS, like other members of the 'cancer/testis antigen' family, is normally expressed in

59 NY-ESO-1 is a "cancer-testis" antigen frequently expressed in epithelia

60 AG-1, TAG-2a, TAG-2b, and TAG-2c) of a novel cancer/testis antigen gene have been identified and are

61 rough this analysis, we show that a class of cancer testis antigen genes undergoes CpG island hypomet

62 ubtypes and two of the AD subtypes expressed cancer testis antigen genes, whereas three AD subtypes e

63 Unlike most cancer/testis antigen genes which are located on the X c

64 nduce helper T cells against melanocytic and cancer-testis antigens, has been shown to induce specifi

65 D3 complexes bound to their pMHC ligand, the cancer-testis antigen HLA-A2/MAGEA4 (230-239).

66 ed immunohistochemical analysis for TILs and cancer testis antigens in 117 cases of epithelial ovaria

67 ntigen-specific T-cell responses against six cancer-testis antigens in peripheral blood lymphocytes f

68 gene, located on chromosome Xq28, encodes a cancer/testis antigen in human.

69 his is the first report on the expression of cancer/testis antigens in chondrosarcoma.

70 cted SPAG5 and TSSK6 as putative immunogenic cancer/testis antigens in multiple cancers.

71 lly expressed antigen in melanoma (PRAME), a cancer-testis antigen, in melanoma progression, focusing

72 Melanoma antigen-A4 (MAGE-A4), a cancer-testis antigen, is expressed in solid tumors and

73 state-associated gene 4 (PAGE4), an X-linked cancer/testis antigen, is highly up-regulated in the epi

74 suggested by identifying reactivation of the cancer-testis antigens MAGE and RAGE in ACHN cells after

75 Three of the 13 antigens were cancer/testis antigens (MAGEA3, SSX2, and NY-ESO-1), whi

76 d genes upregulated in these tumors included cancer-testis antigen MAGEA6 and matrix metalloproteinas

77 clinically relevant peptide derived from the cancer testis antigen melanoma antigen-A4 (MAGE-A4).

78 The cancer/testis antigen New York esophageal squamous cell

79 including endogenous retroviruses and latent cancer testis antigens normally silenced by DNA methylat

80 ften include CD8(+) T cells specific for the cancer testis antigen NY-ESO-1.

81 The cancer-testis antigen NY-ESO-1 is one of the most promis

82 mor shrinkage with antibody responses to the cancer-testis antigen NY-ESO-1, changes in peripheral-bl

83 a naturally processed peptide shared by the cancer-testis antigens NY-ESO-1 and LAGE-1.

84 Salmonella typhimurium engineered to deliver cancer/testis antigen NY-ESO-1 through type III secretio

85 enza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (NY-ESO-1 S-FLU).

86 We studied cross-presentation of the cancer/testis antigen, NY-ESO-1, and the melanoma differ

87 d deletions, fusion events, splice variants, cancer-testis antigens, overexpressed self-antigens, vir

88 815, which expresses the naturally occurring cancer/testis antigen P1A, or the corresponding tumor P1

89 We show here that the cancer/testis antigen PASD1 fulfills this role to suppre

90 , we report findings on the involvement of a cancer/testis antigen, PRAMEL1, in the initiation and ma

91 re, we examined metastasis promoting role of cancer testis antigen SPANXB1 in TNBC and its utility as

92 y expressed antigen in melanoma (PRAME) is a cancer-testis antigen that is expressed in many cancers

93 sts of more than 60 genes, many of which are cancer-testis antigens that are highly expressed in canc

94 breakpoint (SSX) proteins comprise a set of cancer-testis antigens that are upregulated in MHC class

95 ESO-1 thus represents the first example of a cancer/testis antigen that is a also damage-associated m

96 ene 4 (PAGE4) is an intrinsically disordered cancer/testis antigen that is up-regulated in the fetal

97 een subpopulations of TILs and expression of cancer testis antigens was investigated, as well as betw

98 CAGE, a cancer/testis antigen, was originally isolated from the

99 ively strong immunogenicity of a non-mutated cancer/testis antigen, we found that NY-ESO-1 forms poly

100 is a member of the PRAME multigene family of cancer testis antigens, which serve as prognostic marker

101 The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of pati

102 l 94 amino acids of L552S are identical to a cancer testis antigen, XAGE-1, found in Ewing's sarcoma.